NOXXON appoints leading pancreatic cancer experts to scientific advisory board
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by tar…
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by tar…
NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), a biotechnology company whose core focus is on improving cancer treat…
NOXXON Pharma N.V. (Alternext Paris: ALNOX) a clinical-stage biopharmaceutical company primarily focused on cancer treat…
NOXXON Pharma will disclose promising data from two independent clinical Phase IIa studies of the anti-CXCL12/SDF-1 Spie…
NOXXON Pharma announced today the publication of a new study in Cell Reports, entitled "SDF-1 Inhibition Targets the Bon…
NOXXON Pharma today announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa c…